[This Week's IPO] Demand Forecast and Subscription Schedule for the First Week of April

In the first week of this month (April), ImmunOnsia will conduct a demand forecast targeting institutional investors.

◆ImmunOnsia= Established in 2016, ImmunOnsia is a company specializing in immuno-oncology, with Yuhan Corporation holding the largest stake (67%). Its main pipelines are the immuno-oncology drugs 'IMC-001' and 'IMC-002', with IMC-001 currently in Phase 2 clinical trials in Korea and IMC-002 in Phase 1b clinical trials in Korea. The company also holds multiple other new drug candidates.

The total number of shares offered is 9,140,482, all of which are existing shares. The expected offering price ranges from 3,000 to 3,600 KRW, with the total offering amounting to 27.4 billion KRW. The demand forecast for institutional investors will be conducted from the 3rd to the 9th, followed by a public subscription from the 14th to the 15th. The lead underwriter is Korea Investment & Securities.

This content was produced with the assistance of AI translation services.